Please login to the form below
Riovant Sciences
This page shows the latest Riovant Sciences news and features for those working in and with pharma, biotech and healthcare.
Takeda forms new women's health and cancer company
Myovant Sciences will focus on delivering innovative therapies in the two areas, with former Medivation chief medical officer Lynn Seely appointed to lead the business. ... For its tie-up with Takeda, the Japanese firm has granted Myovant Sciences an
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital project manager
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital strategist
-
Competitive
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- GSK reveals plans for £400m R&D facility expansion in England
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med
- Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
